Obama Cools the Stem-Cell Debate
By Jesse Reynolds,
San Francisco Chronicle
| 04. 27. 2009
While juggling a collapsing economy and major initiatives during his first months in office, President Obama tackled - and cooled - a contentious issue that has simmered for almost 10 years: embryonic stem cell research. His March 9 executive order fulfilled a campaign promise to lift his predecessor's restrictions on its federal funding.
The president outlined his new approach, leaving the details up to the National Institutes of Health. A week ago, the NIH unveiled its draft guidelines.
The new regulations would permit federal support for research with stem cell lines derived from embryos that are created, but not used, for fertility treatments. There are hundreds of thousands of such excess embryos in storage, most scheduled for eventual destruction regardless of scientists' activities. At the same time, federal support would not be permitted for work with stem cell lines derived from embryos created with cloning techniques - if any are ever successfully produced.
This is a thoughtful approach, and the right thing to do.
There are very good reasons - technical, ethical and political - why cloning-based stem cell research...
Related Articles
By Carly Mallenbaum, Axios [cites Emily Galpern] | 03.29.2026
More Americans are turning to surrogacy to build their families, as the practice becomes more common and more publicly discussed.
Why it matters: As surrogacy becomes more visible and accessible, ethical, legal and cultural tensions become harder to ignore...
By Carly Mallenbaum, Axios [cites Surrogacy360] | 03.29.2026
Without a federal law, surrogacy in the U.S. is governed by a patchwork of state regulations/
Why it matters: Confusing, varied local rules can determine everything from whether agreements are legally binding to who is recognized as a parent at...
Cathy Tie seems to be good at starting businesses but not so dedicated to maintaining them. CGS, like many others, first heard of her thanks to Caiwei Chen and Antonio Regalado in MIT Technology Review, May 2025, as the partner (perhaps bride) of the notorious Chinese scientist He Jiankui, described in the headline as “China’s Frankenstein.” He prefers “Chinese Darwin.” She ran his Twitter account for a while, contributing such gems as:
Get in luddite, we’re going gene editing...
By Laura DeFrancesco, Nature Biotechnology | 03.17.2026
The first gene editors designed to fix genetic lesions in mutation-agnostic ways are poised to enter the clinic. Tessera Therapeutics and Alltrna, two Flagship Pioneering-funded companies, are gearing up to test novel genetic medicines in humans. Tessera received regulatory clearance...
